Biolase Tech (BLTI) Sees Insider Buying
More News related to BLTI
- BIOLASE Granted First Japanese Patent
- BIOLASE Receives Two New Patents Covering Consumable Laser Tips and Related Technologies
- BIOLASE Commences Shipments of New Waterlase(R) C100 All-Tissue Dental Laser System
- BIOLASE Receives New Patent Covering Core Laser Plus Water Technology
- BIOLASE Countersues Reseller of Modified Lasers
Biolase Technology, Inc. (Nasdaq: BLTI) CEO, Jake St. Philip, bought 30,000 shares on 5/12 at $2.94-$2.95.
In addition, Director Daniel Durrie, bought 20,000 shares on 5/12 at $2.98-$2.99 and Director, James Largent, bought 10,000 shares on 5/12 at $2.93-$2.96.
Biolase Technology, Inc., a medical technology company, engages in the development, manufacture, and marketing of lasers and related products focused on technologies for applications and procedures in dentistry and medicine.
Related Categories
Insider TradesStocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
